NCT02191891 - Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 21, 2014

Primary Completion Date

April 18, 2018

Study Completion Date

April 18, 2018

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Xentuzumab

Patients received intravenous infusion of Xentuzumab 1000 milligram (mg) delivered over 60 minutes per week for 4 weeks, in combination with once daily oral treatment of Afatinib film-coated tablet.

DRUG

Afatinib

Patients received intravenous infusion of Xentuzumab 1000 milligram (mg) delivered over 60 minutes per week for 4 weeks, in combination with once daily oral treatment of Afatinib film-coated tablet.

Trial Locations (10)

100

National Taiwan University Hospital, Taipei

613

Chang Gung Memorial Hospital Chiayi, Chiayi City

704

NCKUH, Tainan City

83301

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

169610

National Cancer Centre Singapore, Singapore

811-1395

National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka

361-771

Chungbuk National University Hospital, Cheongju-si

03722

Severance Hospital, Seoul

135-710

Samsung Medical Center, Seoul

138-736

Asan Medical Center, Seoul